Guardant Health's 15min Chart Indicates RSI Overbought and KDJ Death Cross
ByAinvest
Friday, Aug 29, 2025 1:02 pm ET1min read
GH--
On the buying side, ARK made substantial investments in CRISPR Therapeutics AG (NASDAQ:CRSP) and Intellia Therapeutics Inc (NASDAQ:NTLA). ARK acquired 188,879 shares of CRISPR for $10,259,907 and 359,000 shares of Intellia for $3,776,680 [1]. These purchases indicate a strong bullish stance on gene-editing companies, aligning with ARK's focus on innovative healthcare solutions.
Additionally, ARK increased its investment in PagerDuty Inc (NYSE:PD) by purchasing 90,214 shares, valued at $1,508,378 [1]. This move follows a pattern of buying into the company, suggesting a growing interest in the cloud computing sector.
ARK also sold 1,045 shares of Guardant Health Inc (NASDAQ:GH) for $64,163 [1]. This sale is relatively small compared to other transactions but is part of a series of sales of GH shares over the past week.
The trading activity reflects ARK's strategic pivot towards biotech, particularly companies involved in gene editing and therapeutics, while gradually reducing exposure to certain tech companies. Investors following ARK's movements may interpret these trades as a sign of Wood's shifting focus towards innovative healthcare solutions.
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-shifts-focus-buys-crsp-stock-sells-roku-93CH-4209981
According to the 15-minute chart for Guardant Health, the Relative Strength Index (RSI) has reached overbought levels and the KDJ (Stochastic Oscillator) has formed a death cross at 08/29/2025 13:00. This suggests that the stock price has risen too quickly and is no longer supported by fundamental value, and there is potential for a reversal in momentum towards the downside, with the possibility of further price decreases.
ARK Investment Management, led by Cathie Wood, made significant adjustments to its portfolio on Monday, August 25, 2025. The most notable transaction involved selling 141,194 shares of Roku Inc (NASDAQ:ROKU), worth $13,303,298 [1]. This move is part of a broader trend of reducing ARK's exposure to the streaming device company.On the buying side, ARK made substantial investments in CRISPR Therapeutics AG (NASDAQ:CRSP) and Intellia Therapeutics Inc (NASDAQ:NTLA). ARK acquired 188,879 shares of CRISPR for $10,259,907 and 359,000 shares of Intellia for $3,776,680 [1]. These purchases indicate a strong bullish stance on gene-editing companies, aligning with ARK's focus on innovative healthcare solutions.
Additionally, ARK increased its investment in PagerDuty Inc (NYSE:PD) by purchasing 90,214 shares, valued at $1,508,378 [1]. This move follows a pattern of buying into the company, suggesting a growing interest in the cloud computing sector.
ARK also sold 1,045 shares of Guardant Health Inc (NASDAQ:GH) for $64,163 [1]. This sale is relatively small compared to other transactions but is part of a series of sales of GH shares over the past week.
The trading activity reflects ARK's strategic pivot towards biotech, particularly companies involved in gene editing and therapeutics, while gradually reducing exposure to certain tech companies. Investors following ARK's movements may interpret these trades as a sign of Wood's shifting focus towards innovative healthcare solutions.
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-shifts-focus-buys-crsp-stock-sells-roku-93CH-4209981
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet